![Kok Fatt Lee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kok Fatt Lee
Direktor/Vorstandsmitglied bei
PRESTIGE BIOPHARMA LIMITED
Profil
Kok Fatt Lee is currently the Deputy Chief Executive Officer at Gardens by the Bay and an Independent Director at Prestige BioPharma Ltd. Previously, he worked as a Director at United Overseas Bank Ltd. (Singapore).
He is a graduate of London Business School.
Aktive Positionen von Kok Fatt Lee
| Unternehmen | Position | Beginn |
|---|---|---|
| PRESTIGE BIOPHARMA LIMITED | Direktor/Vorstandsmitglied | - |
Gardens by the Bay
 Gardens by the Bay Other Consumer ServicesConsumer Services Operates as a nature park which engages in developing and managing garden destinations | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Kok Fatt Lee
| Unternehmen | Position | Ende |
|---|---|---|
| UNITED OVERSEAS BANK LIMITED | Direktor/Vorstandsmitglied | - |
Ausbildung von Kok Fatt Lee
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
15
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
United Overseas Bank Ltd. (Singapore)
 United Overseas Bank Ltd. (Singapore) Major BanksFinance Provides wholesale, retail, investment banking, asset management and insurance services | Finance |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gardens by the Bay
Gardens by the Bay Other Consumer ServicesConsumer Services Operates as a nature park which engages in developing and managing garden destinations | Consumer Services |
Prestige BioPharma Ltd.
 Prestige BioPharma Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biosimilars and antibody therapeutics | Health Technology |
